14 completed. 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
Follow Hepatitis D: new trials by email Literature Review of Hepatitis D trials Research Report on Hepatitis D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D hepalatide - Hepatitis D | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 90 | 2024-12-11 | 2026-10-29 |
| Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 23 | 2023-10-07 | 2024-04-24 |
| A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus JNJ-73763989, Placebo, Entecavir (ETV) monohydrate - Hepatitis D, Chronic | Phase 2 | Completed | Janssen Research & Development, LLC | 52 | 2020-09-17 | 2026-07-22 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta | Phase 2 | Completed | Gilead Sciences | 175 | 2019-05-31 | 2024-10-08 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 26 | 2018-08-01 | 2021-12-14 |
| A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Peginterferon Lambda-1A - Hepatitis D, Chronic | Phase 2 | Completed | EIT Pharma, Inc. | 33 | 2016-10-19 | 2026-09-08 |
| A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Myrcludex B, Myrcludex-B, Tenofovir - Chronic Hepatitis D Infection With Hepatitis B | Phase 2 | Completed | Hepatera Ltd. | 120 | 2016-02-16 | 2021-05-10 |
| Titrating-Dose of Lonafarnib in Combination With Ritonavir lonafarnib, Ritonavir - Chronic Delta Hepatitis | Phase 2 | Completed | EIT Pharma, Inc. | 15 | 2015-09-01 | 2026-09-25 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Lonafarnib, Ritonavir, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 22 | 2015-07-29 | 2018-09-25 |
| Lonafarnib for Chronic Hepatitis D Lonafarnib, Placebo - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 14 | 2011-12-01 | 2016-08-31 |
| HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis PEG-IFN alfa-2a, Tenofovir, PEG-IFN alfa-2a, placebo - Hepatitis D | Phase 2 | Completed | HepNet Study House, German Liverfoundation | 70 | 2009-06-01 | 2018-01-29 |
| A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) Peginterferon alfa-2a, Ribavirin - Hepatitis D, Chronic | Phase 2 | Completed | Hoffmann-La Roche | 12 | 2004-09-01 | 2016-07-15 |
| Pegylated Interferon to Treat Chronic Hepatitis D Peginterferon Alpha-2a - Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 13 | 2001-08-01 | 2013-07-10 |
| Lamivudine for Chronic Hepatitis B Lamivudine - Chronic Hepatitis B, Chronic Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 60 | 1995-09-01 | 2008-03-04 |
Hepatitis D, Chronic (7) · Fibrosis (3) · Hepatitis (2) · Hepatitis, Chronic (2) · Liver Diseases (2) · Glomerulonephritis (1) · Hepatitis B, Chronic (1) · Polyarteritis Nodosa (1)
Digestive System Diseases (14) · Hepatitis, Viral, Human (14) · Infections (14) · RNA Virus Infections (14) · Virus Diseases (14) · Hepatitis (12) · Liver Diseases (12) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Chronic Disease (9) · Disease Attributes (9) · Hepatitis, Chronic (7) · Arteritis (1) · Blood-Borne Infections (1)
lonafarnib (4) · Ritonavir (3) · Tenofovir (3) · peginterferon alfa-2a (3) · myrcludex-B (2) · Lamivudine (1) · Ribavirin (1) · bulevirtide (1) · entecavir (1) · peginterferon lambda-1a (1) · tenofovir alafenamide (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · EIT Pharma, Inc. (2) · Shanghai HEP Pharmaceutical Co., Ltd. (2) · Gilead Sciences (1) · HepNet Study House, German Liverfoundation (1) · Hepatera Ltd. (1) · Hoffmann-La Roche (1) · Janssen Research & Development, LLC (1)
United States (6) · Germany (3) · Russia (3) · China (2) · France (2) · Italy (2) · Mongolia (2) · New Zealand (2) · Romania (2) · Australia (1) · Brazil (1) · Greece (1) · Israel (1) · Japan (1) · Moldova (1)
Theo Heller, M.D. (3) · Christopher Koh, M.D. (1) · David Apelian, MD, PhD, MBA (1) · Heiner Wedemeyer, MD, PhD (1) · Heiner Wedemeyer, MD,PhD (1) · Junqi Niu (1) · Michael P. Manns, Prof. Dr. (1) · Oyunbileg Janchiv (1)
PMID 30664876, PMID 26189433, PMID 30516520, PMID 30833068, PMID 34048594, PMID 36113537, PMID 37120031, PMID 37787009, PMID 38340811, PMID 38842520, PMID 39648559, PMID 40087915, PMID 41317314
2019 (1), 2023 (1)